A biochemical fluorometric method for assessing the oxidative properties of HDL

Journal of Lipid Research

Volumn 52, Issue 12, 2011, Pages 2341-2351

  Kelesidis, Theodoros ^a   Currier, Judith S ^a   Huynh, Diana ^a   Meriwether, David ^a   Charles Schoeman, Christina ^a   Reddy, Srinivasa T ^a   Fogelman, Alan M ^a   Navab, Mohamad ^a   Yang, Otto O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dihydrorhodamine 123; Dysfunctional high density lipoprotein; HDL function; Oxidation

Indexed keywords

DIHYDRORHODAMINE 123; HIGH DENSITY LIPOPROTEIN; PRAVASTATIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FLUORESCENCE; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; LIPID OXIDATION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REPRODUCIBILITY;

ANIMALS; APOLIPOPROTEIN A-I; ARTIFACTS; CELL-FREE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENT DYES; FLUOROMETRY; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MALE; MICE; OXIDATION-REDUCTION; REPRODUCIBILITY OF RESULTS; RHODAMINE 123; RHODAMINES; TIME FACTORS;

EID: 81855206678     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D018937     Document Type: Article

References (43)

1. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman. 2009. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 50 (Suppl) : S145-S149.
2. Navab, M., J. A. Berliner, A. D. Watson, S. Y. Hama, M. C. Territo, A. J. Lusis, D. M. Shih, B. J. Van Lenten, J. S. Frank, L. L. Demer, et al. 1996. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16: 831-842. (Pubitemid 26234980)
3. Navab, M., S. Y. Hama, C. J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, N. E. Miller, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41: 1481-1494.
4. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508.
5. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, et al. 2003. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756. (Pubitemid 37498976)
6. Ansell, B. J., G. C. Fonarow, and A. M. Fogelman. 2007. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18: 427-434. (Pubitemid 47051922)
7. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2009. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 58: 2711-2717.
8. Navab, M., S. Y. Hama, G. P. Hough, G. Subbanagounder, S. T. Reddy, and A. M. Fogelman. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42: 1308-1317. (Pubitemid 32744255)
9. Patel, S., B. G. Drew, S. Nakhla, S. J. Duffy, A. J. Murphy, P. J. Barter, K. A. Rye, J. Chin-Dusting, A. Hoang, D. Sviridov, et al. 2009. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 53: 962-971.
10. Undurti, A., Y. Huang, J. A. Lupica, J. D. Smith, J. A. DiDonato, and S. L. Hazen. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284: 30825-30835.
11. Van Lenten, B. J., A. C. Wagner, M. Navab, G. M. Anantharamaiah, S. Hama, S. T. Reddy, and A. M. Fogelman. 2007. Lipoprotein infl ammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48: 2344-2353. (Pubitemid 350058746)
12. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52: 361-373.
13. Esposito, B. P., W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko, and Z. I. Cabantchik. 2003. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 102: 2670-2677. (Pubitemid 37193611)
14. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 285: 2486-2497.
15. Navab, M., G. M. Anantharamaiah, S. Hama, G. Hough, S. T. Reddy, J. S. Frank, D. W. Garber, S. Handattu, and A. M. Fogelman. 2005. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25: 1426-1432. (Pubitemid 40923363)
16. Charles-Schoeman, C., D. Khanna, D. E. Furst, M. McMahon, S. T. Reddy, A. M. Fogelman, H. E. Paulus, G. S. Park, T. Gong, and B. J. Ansell. 2007. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J. Rheumatol. 34: 1459-1464. (Pubitemid 47067979)
17. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
18. Hedrick, C. C., L. W. Castellani, C. H. Warden, D. L. Puppione, and A. J. Lusis. 1993. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J. Biol. Chem. 268: 20676-20682. (Pubitemid 23278985)
19. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
20. Widhalm, K., and R. Pakosta. 1991. Precipitation with polyethylene glycol and density-gradient ultracentrifugation compared for determining high-density lipoprotein subclasses HDL2 and HDL3. Clin. Chem. 37: 238-240. (Pubitemid 21892634)
21. Ren, J., W. Jin, and H. Chen. 2010. oxHDL decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms. Mol. Cell. Biochem. 342: 171-181.
22. Kooy, N. W., J. A. Royall, H. Ischiropoulos, and J. S. Beckman. 1994. Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free Radic. Biol. Med. 16: 149-156. (Pubitemid 24117495)
23. Watanabe, J., V. Grijalva, S. Hama, K. Barbour, F. G. Berger, M. Navab, A. M. Fogelman, and S. T. Reddy. 2009. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J. Biol. Chem. 284: 18292-18301.
24. Kelesidis, T., O. O. Yang, J. S. Currier, K. Navab, A. M. Fogelman, and M. Navab. 2011. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis. 10: 35.
25. Navab, M., G. M. Ananthramaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, G. C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, et al. 2004. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45: 993-1007. (Pubitemid 38679495)
26. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, H. Laks, et al. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88: 2039-2046.
27. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772. (Pubitemid 39390578)
28. Daugherty, A., J. L. Dunn, D. L. Rateri, and J. W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94: 437-444. (Pubitemid 24218123)
29. Anantharamaiah, G. M., T. A. Hughes, M. Iqbal, A. Gawish, P. J. Neame, M. F. Medley, and J. P. Segrest. 1988. Effect of oxidation on the properties of apolipoproteins A-I and A-II. J. Lipid Res. 29: 309-318.
30. Garner, B., P. K. Witting, A. R. Waldeck, J. K. Christison, M. Raftery, and R. Stocker. 1998. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J. Biol. Chem. 273: 6080-6087. (Pubitemid 28144687)
31. Garner, B., A. R. Waldeck, P. K. Witting, K. A. Rye, and R. Stocker. 1998. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273: 6088-6095. (Pubitemid 28144688)
32. Wang, X. S., B. Shao, M. N. Oda, J. W. Heinecke, S. Mahler, and R. Stocker. 2009. A sensitive and specific ELISA detects methionine sulfoxide-containing apolipoprotein A-I in HDL. J. Lipid Res. 50: 586-594.
33. Oram, J. F., and J. W. Heinecke. 2005. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85: 1343-1372. (Pubitemid 41362273)
34. Wardman, P. 2008. Methods to measure the reactivity of peroxynitrite-derived oxidants toward reduced fluoresceins and rhodamines. Methods Enzymol. 441: 261-282.
35. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
36. Sattler, W., J. Christison, and R. Stocker. 1995. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic. Biol. Med. 18: 421-429.
37. Glebska, J., and W. H. Koppenol. 2003. Peroxynitrite-mediated oxidation of dichlorodihydrofluorescein and dihydrorhodamine. Free Radic. Biol. Med. 35: 676-682. (Pubitemid 37101134)
38. Ischiropoulos, H., A. Gow, S. R. Thom, N. W. Kooy, J. A. Royall, and J. P. Crow. 1999. Detection of reactive nitrogen species using 2, 7-dichlorodihydrofluorescein and dihydrorhodamine 123. Methods Enzymol. 301: 367-373. (Pubitemid 28489798)
39. Wardman, P. 2007. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects. Free Radic. Biol. Med. 43: 995-1022. (Pubitemid 47302656)
40. Hallberg, C., M. Haden, M. Bergstrom, G. Hanson, K. Pettersson, C. Westerlund, G. Bondjers, A. M. Ostlund-Lindqvist, and G. Camejo. 1994. Lipoprotein fractionation in deuterium oxide gradients: a procedure for evaluation of antioxidant binding and susceptibility to oxidation. J. Lipid Res. 35: 1-9. (Pubitemid 24027985)
41. Sattler, W., D. Mohr, and R. Stocker. 1994. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 233: 469-489.
42. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478. (Pubitemid 39302636)
43. Panzenböck, U., L. Kritharides, M. Raftery, K. A. Rye, and R. Stocker. 2000. Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J. Biol. Chem. 275: 19536-19544. (Pubitemid 30441546)